Stoke Therapeutics Inc is a biotechnology company focused on developing innovative therapies to treat genetic diseases by harnessing the power of messenger RNA (mRNA) biology. The company is dedicated to addressing the underlying causes of diseases by enhancing the production of proteins through its proprietary platform, which aims to restore the normal function of genes that are dysfunctional due to genetic mutations. By prioritizing precision medicine, Stoke Therapeutics works towards delivering transformative treatments that can improve the quality of life for patients suffering from various neurological disorders and other serious conditions.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced new data from an analysis of nine patients treated with an initial 2 or 3 doses of 70mg, followed by 45mg maintenance dosing in the Phase 1/2a and open-label extension (OLE) studies of zorevunersen. Substantial and durable reductions in convulsive seizure frequency were observed in these patients who received zorevunersen on top of the best available anti-seizure medicines. In addition, patients treated in the OLE studies showed continuous improvements in multiple measures of cognition and behavior with ongoing treatment through 2 years. Zorevunersen was generally well tolerated across the studies. Together, these data support the company’s proposed Phase 3 registrational study regimen and its efforts to develop zorevunersen as a disease-modifying medicine for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene. Zorevunersen is being developed as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced several presentations at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6 – 10, in Los Angeles, California. In addition, the Company will host a virtual event with discussions led by leading clinicians and patient advocates for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific). The Company is advancing zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for the third quarter of 2024 and provided business updates including those related to zorevunersen, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced highlights from presentations at the 15th European Epilepsy Congress (EEC) related to the Company’s work to develop the first disease-modifying medicine for Dravet syndrome. Zorevunersen (STK-001) data showing substantial and sustained reductions in seizures and meaningful improvements in multiple measures of cognition and behavior were presented for the first time in a scientific forum. New data from an analysis of patients treated in the Phase 1/2a ADMIRAL study showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued. In addition, data from a two-year natural history study presented at the meeting showed that despite treatment with standard-of-care antiseizure medications, patients with Dravet syndrome continued to have high seizure rates and plateaued in their neurodevelopment, resulting in a widening gap in development compared to their neurotypical peers.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Olson will be responsible for leading and executing the Company’s global corporate strategy and business development.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced it will present data from its Dravet syndrome clinical program at the 15th European Epilepsy Congress (EEC) taking place September 7 – 11, in Rome, Italy.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that, effective on August 15, 2024, the company granted stock options to purchase an aggregate of 48,400 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for the second quarter of 2024 and provided business updates including those related to zorevunersen (STK-001), the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that, effective on July 15, 2024, the company granted stock options to purchase an aggregate of 122,900 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company’s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his position as Stoke’s Chief Financial Officer effective Tuesday, May 7.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership team, Mr. Hoitt will be responsible for overseeing the Company’s global commercial strategy for STK-001. Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome.
